Search results
Retina UK invites applications for funding for innovative, high quality research projects investigating the causes and potential treatments for all forms of inherited retinal disease. We are particularly keen to receive proposals with demonstrable translational potential.
Stem cells are a special type of cell, which under the right conditions can be encouraged to grow into any other type of cell in the body, including retinal cells (rods, cones and retinal pigment epithelial cells).
The following projects were being funded by Retina UK and have recently come to an end.
Eye2Gene: new publication describes how AI can predict genetic diagnosis from retinal scans
Do you want to win up to £25,000 and feel good about supporting people with inherited progressive sight loss?! 30 Retina UK supporters have won a cash prize so far.
Early results from clinical testing of a gene therapy to treat X-linked retinitis pigmentosa (XLRP) have shown partial reversal of sight loss in some patients.
You may have heard that a cell-based treatment approach (sometimes referred to as a “stem cell treatment”), developed by a company called ReNeuron, is being tested in a clinical trial at Oxford Eye Hospital and other centres in the US and Europe.
Prof John Marshall is the Frost Professor of Ophthalmology at the Institute of Ophthalmology at University College London.
High quality information on genetic testing and counselling for families affected by inherited sight loss is now available in one place thanks to the launch of an innovative new website, Unlock Genetics.
Autosomal dominant inheritance means that the faulty gene is on an autosome (any chromosome other than the sex chromosomes) and that only one faulty copy is needed to cause sight loss.
